Phase 3 Migraine Trial, Recruiting NCT07018713 Sponsor: Merz Therapeutics GmbH Condition: Migraine
Back to Migraine

Phase 3 Migraine Trial, Recruiting

NCT07018713
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with chronic migraine (with or without aura) for at least 12 months, and who can tell the difference between their migraines and other types of headaches
  • People whose migraines first started before the age of 50
  • People who have had at least 15 headache days per month and at least 8 migraine days per month during each of the 3 months before the screening period
  • People who, during the last 28 days of the screening period, recorded at least 15 headache days and at least 8 migraine days in a headache diary

Who may not be able to join:

  • People who have been diagnosed with other primary headache conditions — though tension-type headache is allowed
  • People who have been diagnosed with certain specific migraine or headache conditions, including: aura without headache, migraine with brainstem aura, hemicrania continua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aura without brain injury, migraine aura-triggered seizures, or a previous stroke caused by a migraine
  • People who have been diagnosed with headache types caused by another underlying condition — though medication overuse headache is allowed
  • People who are currently taking more than one prescribed medication to prevent migraines
  • People who stopped taking a specific type of migraine prevention injection (known as an anti-CGRP monoclonal antibody) less than 5 months before the screening period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Merz Medical Expert, Merz Therapeutics

Phone: +49691503

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Merz Therapeutics GmbH
Registry
ClinicalTrials.gov
Start date
21 August 2025
Est. completion
1 October 2027

Where this trial is recruiting

🇦🇹 Austria 🇨🇦 Canada 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇵🇱 Poland 🇸🇰 Slovakia 🇪🇸 Spain 🇨🇭 Switzerland 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov